Trial Profile

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TORL-1-23 (Primary) ; Pegfilgrastim
Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Testicular cancer
Focus Adverse reactions; First in man
Acronyms TRIO049
Sponsors TORL Biotherapeutics

Most Recent Events

07 Oct 2025 According to a TORL BioTherapeutics media release, updated results from the ongoing Phase 1 study will be presented in poster sessions at the 2025 European Society of Medical Oncology Congress (ESMO 2025) in Berlin, Germany.
14 May 2025 Planned End Date changed from 15 Nov 2025 to 15 Nov 2026.
14 May 2025 Planned primary completion date changed from 15 Apr 2025 to 31 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com